Redeye maintains a positive outlook on Ngenic following its Q1 2023 report, which showcased robust growth and impressive margins. The demand for Ngenic's products remain high and the company has issued a SEK10.2m convertible loan to expedite further growth. As a result, we anticipate stronger performance and have adjusted our short-term forecast accordingly. The stellar performance, coupled with the company's strategy to accelerate growth, gives rise to a new fair value range and base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases